Pay in 4 interest-free payments of $43.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
which relies on the Tyramide Signal Amplification (TSA) technology
specifically on a subset of CD4+ T cells in the spleen
CEA was originally described in bile ducts of liver as biliary glycoprotein
BRD7_HUMAN
Anti-human Siglec-3 / CD33 (LintuzumAb Biosimilar) Size:1 mg which relies on the TyramideApplication ELISA, Bioactivity: FACS, Functional assay, Research in vivo Reactivity Human Target Target Name Siglec 3 CD33 Target Uniprot O14793 Overview Catalog# BIO0405SM Product Name Anti human Siglec 3 CD33 (LintuzumAb Biosimilar) Specifications Conjugation None Clone# LintuzumAb Formulation 100 mM Pro Ac 20mM Arg pH 5. 0 Storage For long term storage, the produce should be stored at 20 or lower. Reconstitution Dissolve with sterile ddH2O
US$ 380.50
US$ 17.00
US$ 15.95
US$ 17000.00
US$ 298.00
US$ 17.00
US$ 17.00
